Spyre Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Spyre Therapeutics has a total shareholder equity of $374.4M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $436.1M and $61.7M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$426.00m |
| Equity | US$374.39m |
| Total liabilities | US$61.68m |
| Total assets | US$436.07m |
Recent financial health updates
Aeglea BioTherapeutics (NASDAQ:AGLE) Will Have To Spend Its Cash Wisely
Feb 24
We're A Little Worried About Aeglea BioTherapeutics' (NASDAQ:AGLE) Cash Burn Rate
Oct 28Recent updates
Aeglea BioTherapeutics (NASDAQ:AGLE) Will Have To Spend Its Cash Wisely
Feb 24We're A Little Worried About Aeglea BioTherapeutics' (NASDAQ:AGLE) Cash Burn Rate
Oct 28Aeglea stock jumps ~58% after hours on European nod for enzyme pegzilarginase
Aug 18Aeglea BioTherapeutics GAAP EPS of -$0.27 beats by $0.04, revenue of $0.63M misses by $0.08M
Aug 04Can Aeglea BioTherapeutics (NASDAQ:AGLE) Afford To Invest In Growth?
Jun 09Aeglea Presents Itself As Buy Opportunity After Latest Data Causes Stock To Trade Lower
Dec 07Industry Analysts Just Made A Stunning Upgrade To Their Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Revenue Forecasts
Aug 10Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Just Reported Second-Quarter Earnings And Analysts Are Lifting Their Estimates
Aug 08Aeglea BioTherapeutics EPS misses by $0.14
May 10Aeglea completes patient randomization in late-stage pegzilarginase trial
May 03What You Need To Know About Aeglea BioTherapeutics, Inc.'s (NASDAQ:AGLE) Investor Composition
Mar 17We Think Aeglea BioTherapeutics (NASDAQ:AGLE) Needs To Drive Business Growth Carefully
Feb 10
Financial Position Analysis
Short Term Liabilities: SYRE's short term assets ($435.7M) exceed its short term liabilities ($22.1M).
Long Term Liabilities: SYRE's short term assets ($435.7M) exceed its long term liabilities ($39.6M).
Debt to Equity History and Analysis
Debt Level: SYRE is debt free.
Reducing Debt: SYRE has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: SYRE has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: SYRE has sufficient cash runway for 2.3 years if free cash flow continues to reduce at historical rates of 14.1% each year.